

Alberto Lleñ³

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3625475/publications.pdf>

Version: 2024-02-01

279
papers

20,974
citations

23544

58
h-index

13365

130
g-index

306
all docs

306
docs citations

306
times ranked

22627
citing authors

#	ARTICLE	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. <i>Nature Genetics</i> , 2013, 45, 1452-1458.	9.4	3,741
2	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	9.4	1,962
3	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
4	Rare coding variants in <i>PLCG2</i> , <i>ABI3</i> , and <i>TREM2</i> implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	9.4	783
5	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
6	<i>TREM2</i> mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. <i>Science Translational Medicine</i> , 2014, 6, 243ra86.	5.8	600
7	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	3.8	501
8	<scp>sTREM</scp> 2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. <i>EMBO Molecular Medicine</i> , 2016, 8, 466-476.	3.3	392
9	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimer's and Dementia</i> , 2013, 9, 251-261.	0.4	344
10	Frontotemporal dementia and its subtypes: a genome-wide association study. <i>Lancet Neurology</i> , The, 2014, 13, 686-699.	4.9	302
11	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
12	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
13	Nonsteroidal anti-inflammatory drugs lower A β ₄₂ and change presenilin 1 conformation. <i>Nature Medicine</i> , 2004, 10, 1065-1066.	15.2	206
14	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
15	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 111-126.	1.2	197
16	Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. <i>Neurobiology of Aging</i> , 2010, 31, 725-731.	1.5	196
17	Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association study. <i>Lancet Neurology</i> , The, 2018, 17, 64-74.	4.9	195
18	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimer's and Dementia</i> , 2016, 12, 154-163.	0.4	179

#	ARTICLE	IF	CITATIONS
19	The <i>MS4A</i> gene cluster is a key modulator of soluble TREM2 and Alzheimer's disease risk. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	170
20	Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet</i> , The, 2020, 395, 1988-1997.	6.3	164
21	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144
22	Reduced Slow-Wave Sleep Is Associated with High Cerebrospinal Fluid A β 42 Levels in Cognitively Normal Elderly. <i>Sleep</i> , 2016, 39, 2041-2048.	0.6	140
23	Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. <i>Lancet Neurology</i> , The, 2018, 17, 860-869.	4.9	140
24	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
25	Familial Alzheimer's Disease Presenilin 1 Mutations Cause Alterations in the Conformation of Presenilin and Interactions with Amyloid Precursor Protein. <i>Journal of Neuroscience</i> , 2005, 25, 3009-3017.	1.7	139
26	Confluence of α -Synuclein, Tau, and β -Amyloid Pathologies in Dementia With Lewy Bodies. <i>Journal of Neuropathology and Experimental Neurology</i> , 2013, 72, 1203-1212.	0.9	138
27	Qualitative changes in human β -secretase underlie familial Alzheimer's disease. <i>Journal of Experimental Medicine</i> , 2015, 212, 2003-2013.	4.2	134
28	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.4	134
29	Association of Cerebral Amyloid- β Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133
30	Amyloid precursor protein metabolism and inflammation markers in preclinical Alzheimer disease. <i>Neurology</i> , 2015, 85, 626-633.	1.5	131
31	MicroRNA Profile in Patients with Alzheimer's Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Fluid Samples. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 483-491.	1.2	126
32	Dementia Risk in Parkinson Disease. <i>Archives of Neurology</i> , 2011, 68, 359-64.	4.9	125
33	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018, 14, 340-351.	0.4	122
34	Tau Enhances α -Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy. <i>PLoS ONE</i> , 2011, 6, e26609.	1.1	115
35	Changes in Synaptic Proteins Precede Neurodegeneration Markers in Preclinical Alzheimer's Disease Cerebrospinal Fluid. <i>Molecular and Cellular Proteomics</i> , 2019, 18, 546-560.	2.5	115
36	Cerebrospinal fluid β -amyloid and phospho-tau biomarker interactions affecting brain structure in preclinical Alzheimer disease. <i>Annals of Neurology</i> , 2014, 76, 223-230.	2.8	110

#	ARTICLE	IF	CITATIONS
37	Pittsburgh compound B imaging and cerebrospinal fluid amyloid- β in a multicentre European memory clinic study. <i>Brain</i> , 2016, 139, 2540-2553.	3.7	107
38	Relationship Between β -Secretase, Inflammation and Core Cerebrospinal Fluid Biomarkers for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 157-167.	1.2	106
39	Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 1815-1824.	1.7	104
40	Frequency of Mutations in the Presenilin and Amyloid Precursor Protein Genes in Early-Onset Alzheimer Disease in Spain. <i>Archives of Neurology</i> , 2002, 59, 1759.	4.9	103
41	Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. <i>Acta Neuropathologica</i> , 2013, 125, 201-213.	3.9	103
42	CSF sAPP β , YKL-40, and neurofilament light in frontotemporal lobar degeneration. <i>Neurology</i> , 2017, 89, 178-188.	1.5	100
43	YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. <i>Journal of Neuroinflammation</i> , 2017, 14, 118.	3.1	99
44	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
45	Assessing the role of the TREM2 p.R47H variant as a risk factor for Alzheimer's disease and frontotemporal dementia. <i>Neurobiology of Aging</i> , 2014, 35, 444.e1-444.e4.	1.5	92
46	<i>APOE</i> -by-sex interactions on brain structure and metabolism in healthy elderly controls. <i>Oncotarget</i> , 2015, 6, 26663-26674.	0.8	92
47	Synaptic phosphorylated β -synuclein in dementia with Lewy bodies. <i>Brain</i> , 2017, 140, 3204-3214.	3.7	90
48	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.	0.4	90
49	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
50	<i>TBK1</i> Mutation Spectrum in an Extended European Patient Cohort with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis. <i>Human Mutation</i> , 2017, 38, 297-309.	1.1	87
51	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. <i>Neurology</i> , 2021, 96, e671-e683.	1.5	84
52	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.4	82
53	Relationship between cortical thickness and cerebrospinal fluid YKL-40 in prodementia stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2018-2023.	1.5	75
54	Clinical, Pathological, and Biochemical Spectrum of Alzheimer Disease Associated With PS-1 Mutations. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 146-156.	0.6	73

#	ARTICLE	IF	CITATIONS
55	Trisomy 21 activates the kynurenine pathway via increased dosage of interferon receptors. <i>Nature Communications</i> , 2019, 10, 4766.	5.8	73
56	A metabolite-based machine learning approach to diagnose Alzheimer's type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 933-938.	1.8	70
57	Activity of γ -Secretase on Substrates Other than APP. <i>Current Topics in Medicinal Chemistry</i> , 2008, 8, 9-16.	1.0	67
58	Non-Fibrillar Oligomeric Amyloid- β^2 within Synapses. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 787-800.	1.2	65
59	Longitudinal brain structural changes in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 499-509.	0.4	65
60	Neuropsychological deficits in patients with cognitive complaints after COVID-19. <i>Brain and Behavior</i> , 2022, 12, e2508.	1.0	64
61	Current Therapeutic Options for Alzheimers Disease. <i>Current Genomics</i> , 2007, 8, 550-558.	0.7	63
62	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	3.0	62
63	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.4	62
64	Mild cholesterol depletion reduces amyloid- β^2 production by impairing APP trafficking to the cell surface. <i>Journal of Neurochemistry</i> , 2009, 110, 220-230.	2.1	60
65	CSF sAPP β^2 , YKL-40, and NfL along the ALS-FTD spectrum. <i>Neurology</i> , 2018, 91, e1619-e1628.	1.5	59
66	PLD3 in non-familial Alzheimer's disease. <i>Nature</i> , 2015, 520, E3-E5.	13.7	58
67	Prevalence of the apolipoprotein E ϵ^4 allele in amyloid β^2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
68	Low Density Lipoprotein Receptor-related Protein (LRP) Interacts with Presenilin 1 and Is a Competitive Substrate of the Amyloid Precursor Protein (APP) for β^2 -Secretase. <i>Journal of Biological Chemistry</i> , 2005, 280, 27303-27309.	1.6	57
69	Obesity and Alzheimer's disease, does the obesity paradox really exist? A magnetic resonance imaging study. <i>Oncotarget</i> , 2018, 9, 34691-34698.	0.8	57
70	Analysis of the <i>CHCHD10</i> gene in patients with frontotemporal dementia and amyotrophic lateral sclerosis from Spain. <i>Brain</i> , 2015, 138, e400-e400.	3.7	56
71	The use of biomarkers for the etiologic diagnosis of MCI in Europe: An EADC survey. <i>Alzheimer's and Dementia</i> , 2015, 11, 195.	0.4	56
72	Prevalence of Sleep Disorders in Adults With Down Syndrome: A Comparative Study of Self-Reported, Actigraphic, and Polysomnographic Findings. <i>Journal of Clinical Sleep Medicine</i> , 2018, 14, 1725-1733.	1.4	56

#	ARTICLE	IF	CITATIONS
73	Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 26.	3.0	56
74	Plasma phosphorylated TDP-43 levels are elevated in patients with frontotemporal dementia carrying a C9orf72 repeat expansion or a GRN mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 684-691.	0.9	55
75	Use of amyloid-PET to determine cutpoints for CSF markers. <i>Neurology</i> , 2016, 86, 50-58.	1.5	54
76	A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes. <i>JAMA Neurology</i> , 2018, 75, 738.	4.5	54
77	Motor cortex transcriptome reveals microglial key events in amyotrophic lateral sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	54
78	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A Multicenter Study in Spain. <i>Journal of Alzheimer's Disease</i> , 2014, 39, 719-726.	1.2	53
79	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. <i>Acta Neuropathologica</i> , 2017, 134, 475-487.	3.9	53
80	GBA and APOE ϵ 4 associate with sporadic dementia with Lewy bodies in European genome wide association study. <i>Scientific Reports</i> , 2019, 9, 7013.	1.6	53
81	Clinical, Neuropathologic, and Biochemical Profile of the Amyloid Precursor Protein I716F Mutation. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 53-59.	0.9	52
82	Nanoscale structure of amyloid- β 2 plaques in Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 5181.	1.6	52
83	Ante mortem cerebrospinal fluid tau levels correlate with postmortem tau pathology in frontotemporal lobar degeneration. <i>Annals of Neurology</i> , 2017, 82, 247-258.	2.8	51
84	Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease. <i>Oncotarget</i> , 2017, 8, 104706-104716.	0.8	51
85	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S87-S98.	1.2	50
86	Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer's disease pathogenesis. <i>Nature Neuroscience</i> , 2019, 22, 1258-1268.	7.1	48
87	Cerebral amyloid angiopathy in Down syndrome and sporadic and autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 1251-1260.	0.4	47
88	Association of Alzheimer Disease With Life Expectancy in People With Down Syndrome. <i>JAMA Network Open</i> , 2022, 5, e2212910.	2.8	47
89	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
90	Notch1 Competes with the Amyloid Precursor Protein for β -Secretase and Down-regulates Presenilin-1 Gene Expression. <i>Journal of Biological Chemistry</i> , 2003, 278, 47370-47375.	1.6	45

#	ARTICLE	IF	CITATIONS
91	MAPT H1 haplotype is associated with enhanced β -synuclein deposition in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2013, 34, 936-942.	1.5	45
92	Mendelian genes for Parkinson's disease contribute to the sporadic forms of the disease. <i>Human Molecular Genetics</i> , 2015, 24, 2023-2034.	1.4	45
93	Regional Overlap of Pathologies in Lewy Body Disorders. <i>Journal of Neuropathology and Experimental Neurology</i> , 2017, 76, 216-224.	0.9	45
94	CSF microRNA Profiling in Alzheimer's Disease: a Screening and Validation Study. <i>Molecular Neurobiology</i> , 2017, 54, 6647-6654.	1.9	45
95	Cortical microstructure in the behavioural variant of frontotemporal dementia: looking beyond atrophy. <i>Brain</i> , 2019, 142, 1121-1133.	3.7	45
96	Analysis of known amyotrophic lateral sclerosis and frontotemporal dementia genes reveals a substantial genetic burden in patients manifesting both diseases not carrying the <i>C9orf72</i> expansion mutation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 162-168.	0.9	44
97	The Sant Pau Initiative on Neurodegeneration (SPIN) cohort: A data set for biomarker discovery and validation in neurodegenerative disorders. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2019, 5, 597-609.	1.8	44
98	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	1.4	44
99	β -Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 1513-1527.	1.0	43
100	Cerebrospinal Fluid Anti-Amyloid- β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 1-7.	1.2	43
101	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	2.4	42
102	Cortical microstructural correlates of astrogliosis in autosomal-dominant Alzheimer disease. <i>Neurology</i> , 2020, 94, e2026-e2036.	1.5	42
103	Homocysteine and Cognitive Impairment. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 506-512.	0.7	41
104	Posttranslational Nitro-Glycative Modifications of Albumin in Alzheimer's Disease: Implications in Cytotoxicity and Amyloid- β Peptide Aggregation. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 643-657.	1.2	41
105	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	3.0	40
106	Serum neurofilament light chain predicts long-term prognosis in Guillain-Barré syndrome patients. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 70-77.	0.9	40
107	Cerebral Amyloid Angiopathy-Related Atraumatic Convexal Subarachnoid Hemorrhage: An ARIA before the Tsunami. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 710-717.	2.4	39
108	A <i>C6orf10/LOC101929163</i> locus is associated with age of onset in <i>C9orf72</i> carriers. <i>Brain</i> , 2018, 141, 2895-2907.	3.7	39

#	ARTICLE	IF	CITATIONS
109	Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 539-546.	1.2	38
110	Challenges associated with biomarker-based classification systems for Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 346-357.	1.2	37
111	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	1.1	36
112	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 87, 139.e1-139.e7.	1.5	35
113	Investigation of the role of rare TREM2 variants in frontotemporal dementia subtypes. <i>Neurobiology of Aging</i> , 2014, 35, 2657.e13-2657.e19.	1.5	34
114	Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia: a European early-onset dementia consortium study. <i>Neurobiology of Aging</i> , 2015, 36, 2005.e15-2005.e22.	1.5	34
115	Exome sequencing in a consanguineous family clinically diagnosed with early-onset Alzheimer's disease identifies a homozygous CTSF mutation. <i>Neurobiology of Aging</i> , 2016, 46, 236.e1-236.e6.	1.5	34
116	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, 1329-1341.	0.4	34
117	Early-Onset Familial Lewy Body Dementia With Extensive Tauopathy: A Clinical, Genetic, and Neuropathological Study. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 73-82.	0.9	33
118	Autosomal dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter A β production. <i>Journal of Neurochemistry</i> , 2014, 128, 330-339.	2.1	33
119	Different pattern of CSF glial markers between dementia with Lewy bodies and Alzheimer's disease. <i>Scientific Reports</i> , 2019, 9, 7803.	1.6	33
120	Cerebrospinal fluid A β 40 peptides increase in Alzheimer's disease and are highly correlated with phospho-tau in control individuals. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 123.	3.0	33
121	State of the art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 159-177.	0.4	33
122	Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer's disease in adults with Down syndrome. <i>Nature Communications</i> , 2021, 12, 4304.	5.8	33
123	Association of Apolipoprotein E ϵ 4 Allele With Clinical and Multimodal Biomarker Changes of Alzheimer Disease in Adults With Down Syndrome. <i>JAMA Neurology</i> , 2021, 78, 937.	4.5	32
124	Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia. <i>Translational Neurodegeneration</i> , 2021, 10, 50.	3.6	32
125	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	1.5	30
126	Down syndrome, Alzheimer disease, and cerebral amyloid angiopathy: The complex triangle of brain amyloidosis. <i>Developmental Neurobiology</i> , 2019, 79, 716-737.	1.5	30

#	ARTICLE	IF	CITATIONS
127	Clinical and video-polysomnographic analysis of rapid eye movement sleep behavior disorder and other sleep disturbances in dementia with Lewy bodies. <i>Sleep</i> , 2019, 42, .	0.6	30
128	Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1206-1214.	0.9	30
129	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2022, 17, 27.	4.4	30
130	Heritability and genetic variance of dementia with Lewy bodies. <i>Neurobiology of Disease</i> , 2019, 127, 492-501.	2.1	29
131	Diagnostic and prognostic performance and longitudinal changes in plasma neurofilament light chain concentrations in adults with Down syndrome: a cohort study. <i>Lancet Neurology</i> , The, 2021, 20, 605-614.	4.9	29
132	Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 909-918.	1.2	28
133	C-terminal fragments of the amyloid precursor protein in cerebrospinal fluid as potential biomarkers for Alzheimer disease. <i>Scientific Reports</i> , 2017, 7, 2477.	1.6	28
134	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 409.	1.7	28
135	APOE ϵ 4 genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 65.	3.0	28
136	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 33-40.	1.5	27
137	Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 618-628.	0.4	27
138	Downregulation of miR-335-5P in Amyotrophic Lateral Sclerosis Can Contribute to Neuronal Mitochondrial Dysfunction and Apoptosis. <i>Scientific Reports</i> , 2020, 10, 4308.	1.6	26
139	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.4	26
140	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1585-1595.	1.2	25
141	Cerebrospinal fluid mitochondrial DNA in the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2017, 53, 192.e1-192.e4.	1.5	24
142	Detection of amyloid beta peptides in body fluids for the diagnosis of Alzheimer's disease: Where do we stand?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2020, 57, 99-113.	2.7	24
143	Active bilingualism delays the onset of mild cognitive impairment. <i>Neuropsychologia</i> , 2020, 146, 107528.	0.7	24
144	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.4	23

#	ARTICLE	IF	CITATIONS
145	Acetylcholinesterase Modulates Presenilin-1 Levels and β -Secretase Activity. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 911-924.	1.2	22
146	Characteristics of subjective cognitive decline associated with amyloid positivity. <i>Alzheimer's and Dementia</i> , 2022, 18, 1832-1845.	0.4	22
147	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2019, 76, 215.e9-215.e14.	1.5	21
148	Cerebrospinal fluid profile of NPTX2 supports role of Alzheimer's disease-related inhibitory circuit dysfunction in adults with Down syndrome. <i>Molecular Neurodegeneration</i> , 2020, 15, 46.	4.4	21
149	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	1.7	20
150	Rare nonsynonymous variants in SORT1 are associated with increased risk for frontotemporal dementia. <i>Neurobiology of Aging</i> , 2018, 66, 181.e3-181.e10.	1.5	19
151	Cortical microstructure in the amyotrophic lateral sclerosis-frontotemporal dementia continuum. <i>Neurology</i> , 2020, 95, e2565-e2576.	1.5	19
152	Biomarker counseling, disclosure of diagnosis and follow-up in patients with mild cognitive impairment: A European Alzheimer's disease consortium survey. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 324-333.	1.3	19
153	Has the time arrived for cerebrospinal fluid biomarkers in psychiatric disorders?. <i>Clinica Chimica Acta</i> , 2019, 491, 81-84.	0.5	18
154	Annexin A5 prevents amyloid- β -induced toxicity in choroid plexus: implication for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 9391.	1.6	18
155	Different Inflammatory Signatures in Alzheimer's Disease and Frontotemporal Dementia Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 629-640.	1.2	18
156	The $A\beta_{1-42}/A\beta_{1-40}$ ratio in CSF is more strongly associated to tau markers and clinical progression than $A\beta_{1-42}$ alone. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 20.	3.0	18
157	Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration. <i>JAMA Network Open</i> , 2022, 5, e229588.	2.8	18
158	Impact of CSF storage volume on the analysis of Alzheimer's disease biomarkers on an automated platform. <i>Clinica Chimica Acta</i> , 2019, 490, 98-101.	0.5	17
159	Elevated YKL-40 and low sAPP β :YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTL. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 180-186.	0.9	17
160	Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease: A paired CSF and plasma study. <i>Alzheimer's and Dementia</i> , 2021, 17, 605-617.	0.4	17
161	Clinical Subtypes of Dementia with Lewy Bodies Based on the Initial Clinical Presentation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 505-513.	1.2	16
162	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 712545.	1.7	16

#	ARTICLE	IF	CITATIONS
163	Uncommon polymorphism in the presenilin genes in human familial Alzheimer's disease: not to be mistaken with a pathogenic mutation. <i>Neuroscience Letters</i> , 2002, 318, 166-168.	1.0	15
164	No supportive evidence for TIA1 gene mutations in a European cohort of ALS-FTD spectrum patients. <i>Neurobiology of Aging</i> , 2018, 69, 293.e9-293.e11.	1.5	15
165	Feasibility of Lumbar Puncture in the Study of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Subjects with Down Syndrome. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1489-1496.	1.2	14
166	New developments of biofluid-based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia. <i>Alzheimer's and Dementia</i> , 2022, 18, 2292-2307.	0.4	14
167	Copy number variation analysis of the 17q21.31 region and its role in neurodegenerative diseases. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2016, 171, 175-180.	1.1	13
168	APP-derived peptides reflect neurodegeneration in frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 2518-2530.	1.7	13
169	A comprehensive screening of copy number variability in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2019, 75, 223.e1-223.e10.	1.5	13
170	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 213-225.	1.2	13
171	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , 2021, 17, 1452-1464.	0.4	13
172	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6891.	1.8	13
173	Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2017, 49, 214.e13-214.e15.	1.5	12
174	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	1.2	12
175	Early detection of subtle motor dysfunction in cognitively normal subjects with amyloid- β^2 positivity. <i>Cortex</i> , 2019, 121, 117-124.	1.1	12
176	Diagnostic Utility of Measuring Cerebral Atrophy in the Behavioral Variant of Frontotemporal Dementia and Association With Clinical Deterioration. <i>JAMA Network Open</i> , 2021, 4, e211290.	2.8	12
177	Cerebral perfusion and haemodynamics measured by SPET in symptom-free patients with transient ischaemic attack: clinical implications. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 1828-1835.	3.3	11
178	Data driven diagnostic classification in Alzheimer's disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of A β^2 species. <i>NeuroImage: Clinical</i> , 2018, 20, 603-610.	1.4	11
179	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis. <i>Neurobiology of Disease</i> , 2019, 124, 428-438.	2.1	11
180	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021, 17, 1499-1508.	0.4	11

#	ARTICLE	IF	CITATIONS
181	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	1.2	10
182	Cortical microstructure in primary progressive aphasia: a multicenter study. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 27.	3.0	10
183	Presenilin-1 influences processing of the acetylcholinesterase membrane anchor PRiMA. <i>Neurobiology of Aging</i> , 2014, 35, 1526-1536.	1.5	9
184	Cerebrospinal fluid Presenilin-1 increases at asymptomatic stage in genetically determined Alzheimer's disease. <i>Molecular Neurodegeneration</i> , 2016, 11, 66.	4.4	9
185	Assessing the role of TUBA4A gene in frontotemporal degeneration. <i>Neurobiology of Aging</i> , 2016, 38, 215.e13-215.e14.	1.5	9
186	Monoaminergic impairment in Down syndrome with Alzheimer's disease compared to early-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 99-111.	1.2	9
187	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	1.7	9
188	Leveraging large multi-center cohorts of Alzheimer disease endophenotypes to understand the role of Klotho heterozygosity on disease risk. <i>PLoS ONE</i> , 2022, 17, e0267298.	1.1	9
189	Early Cerebellar Hypometabolism in Patients With Frontotemporal Dementia Carrying the C9orf72 Expansion. <i>Alzheimer Disease and Associated Disorders</i> , 2015, 29, 353-356.	0.6	8
190	Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases. <i>Frontiers of Neurology and Neuroscience</i> , 2016, 39, 117-123.	3.0	8
191	Cerebral changes and disrupted gray matter cortical networks in asymptomatic older adults at risk for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 64, 58-67.	1.5	8
192	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 99, 99.e15-99.e22.	1.5	8
193	CSF sTREM2 is elevated in a subset in GRN-related frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 103, 158.e1-158.e5.	1.5	8
194	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2021, 10, 37.	3.6	8
195	Disease-Specific Changes in Reelin Protein and mRNA in Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 1252.	1.8	8
196	Kidins220 Correlates with Tau in Alzheimer's Disease Brain and Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 1327-1333.	1.2	7
197	Obesity impacts brain metabolism and structure independently of amyloid and tau pathology in healthy elderly. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12052.	1.2	7
198	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7

#	ARTICLE	IF	CITATIONS
199	Increased plasma neurofilament light chain levels in patients with type-1 diabetes with impaired awareness of hypoglycemia. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001516.	1.2	7
200	Multilingualism in semantic dementia: language-dependent lexical retrieval from degraded conceptual representations. <i>Aphasiology</i> , 2021, 35, 240-266.	1.4	7
201	Biomarkers in neurological disorders: a fast-growing market. <i>Brain Communications</i> , 2021, 3, fcab086.	1.5	7
202	Metabolite Signature of Alzheimer's Disease in Adults with Down Syndrome. <i>Annals of Neurology</i> , 2021, 90, 407-416.	2.8	7
203	Sex-Specific Metabolic Pathways Were Associated with Alzheimer's Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort. <i>Biomedicines</i> , 2021, 9, 1610.	1.4	7
204	Blood amyloid and tau biomarkers as predictors of cerebrospinal fluid profiles. <i>Journal of Neural Transmission</i> , 2022, 129, 231-237.	1.4	7
205	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration. <i>Molecular Neurodegeneration</i> , 2022, 17, 29.	4.4	7
206	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	7
207	Dementia and epilepsy. <i>Neurology</i> , 2020, 95, 1074-1075.	1.5	6
208	Race and Alzheimer Disease Biomarkers. <i>Neurology: Genetics</i> , 2021, 7, e574.	0.9	6
209	VAMP-2 is a surrogate cerebrospinal fluid marker of Alzheimer-related cognitive impairment in adults with Down syndrome. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 119.	3.0	6
210	Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis: New Insights From Biomarker Studies. <i>Frontiers in Neurology</i> , 2021, 12, 750543.	1.1	6
211	A Common Variant in the MC1R Gene (p.V92M) is associated with Alzheimer's Disease Risk. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 1065-1074.	1.2	5
212	The pitfalls of biomarker-based classification schemes. <i>Alzheimer's and Dementia</i> , 2017, 13, 1072-1074.	0.4	5
213	Cerebrospinal fluid mitochondrial DNA levels in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1535-1538.	1.4	5
214	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 163-175.	1.2	5
215	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 160.	3.0	5
216	O5a02a04: DOWN ALZHEIMER BARCELONA NEUROIMAGING INITIATIVE (DABNI): A PROSPECTIVE LONGITUDINAL BIOMARKER COHORT TO STUDY ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2016, 12, P380.	0.4	4

#	ARTICLE	IF	CITATIONS
217	Distinct Clinical Features and Outcomes in Motor Neuron Disease Associated with Behavioural Variant Frontotemporal Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2018, 45, 220-231.	0.7	4
218	Evaluation of biochemical and hematological parameters in adults with Down syndrome. <i>Scientific Reports</i> , 2020, 10, 13755.	1.6	4
219	Sex differences in the behavioral variant of frontotemporal dementia: A new window to executive and behavioral reserve. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	4
220	Importance of cerebrospinal fluid storage conditions for the Alzheimer's disease diagnostics on an automated platform. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1058-1063.	1.4	4
221	Myelin loss in <i>C9orf72</i> hexanucleotide expansion carriers. <i>Journal of Neuroscience Research</i> , 2022, 100, 1862-1875.	1.3	4
222	[O3â€“10â€“03]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY. <i>Alzheimer's and Dementia</i> , 2017, 13, P924.	0.4	3
223	El Alzheimer, la enfermedad ignorada. <i>Medicina ClÃnica</i> , 2018, 150, 432-433.	0.3	3
224	P4-267: CORE ALZHEIMER'S DISEASE CSF BIOMARKERS IN DOWN SYNDROME. , 2014, 10, P882-P882.		2
225	Effect of <i>REST</i> on brain metabolism in the Alzheimer disease continuum. <i>Annals of Neurology</i> , 2015, 78, 661-662.	2.8	2
226	Alzheimer's disease: An ignored condition. <i>Medicina ClÃnica (English Edition)</i> , 2018, 150, 432-433.	0.1	2
227	Amyloid imaging in depression: a predictor of Alzheimer's disease?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 711-713.	3.3	1
228	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study. , 2015, 11, P297-P297.		1
229	P1-115: Consensus guidelines to perform lumbar puncture for CSF sampling in patients with neurological conditions. , 2015, 11, P384-P384.		1
230	P1â€“277: CORRELATION BETWEEN INNOTESTÂ® AND THE FULLY AUTOMATED LUMIPULSEÂ® G PLATFORM FOR THE ANALYSIS OF Î²â€“AMYLOID 1â€“42 AND TOTAL TAU. <i>Alzheimer's and Dementia</i> , 2018, 14, P388.	0.4	1
231	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimer's and Dementia</i> , 2020, 16, e036954.	0.4	1
232	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047209.	0.4	1
233	The Added Value of Tau-PET in the Assessment of Progressive Supranuclear Palsy. <i>Clinical Nuclear Medicine</i> , 2020, 45, e239-e240.	0.7	1
234	Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	1

#	ARTICLE	IF	CITATIONS
235	Calsyntenin1 is a cerebrospinal fluid marker of frontotemporal dementia-related synapse degeneration. Alzheimer's and Dementia, 2021, 17, .	0.4	1
236	Exome sequencing identifies rare damaging variants in the ATB8B4 and ABCA1 genes as novel risk factors for Alzheimer's disease.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055982.	0.4	1
237	P3-230: CSF β -AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P715-P715.		0
238	IC-P-217: CSF β -AMYLOID AND PHOSHO-TAU INTERACTIONS ON BRAIN STRUCTURE IN PRECLINICAL AD. , 2014, 10, P117-P117.		0
239	P1-121: Comparison of different β -amyloid isoforms in CSF to detect amyloid pathology in cognitively normal subjects and patients with dementia. , 2015, 11, P387-P387.		0
240	P4-122: Prevalence of Vascular Risk Factors in Different Stages of Prodromal Alzheimer's Disease and Its Influence on Cognitive Decline. Alzheimer's and Dementia, 2016, 12, P1059.	0.4	0
241	P2-424: Obesity is Associated With Increased CSF Phospho-TAU Levels and Cognitive Decline in Healthy Elderly. , 2016, 12, P807-P807.		0
242	O5-05-02: EVALUATION OF SYNAPTIC PROTEINS AS CEREBROSPINAL FLUID STAGE BIOMARKERS FOR ALZHEIMER'S DISEASE. , 2016, 12, P388-P388.		0
243	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau. , 2016, 12, P321-P321.		0
244	[O1-06-02]: BIPHASIC MODEL IN PRECLINICAL ALZHEIMER'S DISEASE: AV45 PET, CSF TAU AND CORTICAL THICKNESS. Alzheimer's and Dementia, 2017, 13, P201.	0.4	0
245	[P1-366]: WEIGHT LOSS MIGHT BE A NON-COGNITIVE SIGN OF PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P399.	0.4	0
246	[P3-274]: STRUCTURAL CORRELATES OF ALZHEIMER'S DISEASE AND AGING IN DOWN SYNDROME: AN MRI STUDY. Alzheimer's and Dementia, 2017, 13, P1048.	0.4	0
247	[P1-238]: THE SAPP β /YKL40 RATIO IN CEREBROSPINAL FLUID AS A DIAGNOSTIC MARKER IN FRONTOTEMPORAL LOBAR DEGENERATION: A PATHOLOGICAL STUDY. Alzheimer's and Dementia, 2017, 13, P335.	0.4	0
248	[P1-289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF β OR AMYLOID-PET) IN THE EMIFAD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.4	0
249	[P2-259]: NETWORK ANALYSIS OF THE CSF PROTEOME IDENTIFIES SYNAPTIC PROTEINS OF HIPPOCAMPAL ORIGIN AS PUTATIVE BIOMARKERS FOR AD-RELATED SYNAPSE LOSS. Alzheimer's and Dementia, 2017, 13, P712.	0.4	0
250	P3-233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFAD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.4	0
251	P4-076: CEREBROSPINAL FLUID CORE BIOMARKERS ALLOW AN ACCURATE DIAGNOSIS OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P1463.	0.4	0
252	F1-02-04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFAD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P204.	0.4	0

#	ARTICLE	IF	CITATIONS
253	P2â€262: A CEREBROSPINAL FLUID PANEL OF SYNAPTIC PROTEINS ACROSS THE ENTIRE ALZHEIMER'S DISEASE CONTINUUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P777.	0.4	0
254	P3â€394: CORTICAL MEAN DIFFUSIVITY MAY BE MORE SENSITIVE IN DETECTING STRUCTURAL CHANGES IN FRONTOTEMPORAL DEMENTIA THAN CORTICAL THICKNESS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1248.	0.4	0
255	O5â€04â€01: A RARE GENETIC VARIANT IN THE <i>PLCG2</i> GENE IS ASSOCIATED WITH A REDUCED RISK OF ALL MAJOR TYPES OF DEMENTIA AND AN INCREASED RISK TO REACH AN EXTREMELY OLD AGE. <i>Alzheimer's and Dementia</i> , 2018, 14, P1648.	0.4	0
256	P1â€293: IDENTIFICATION OF EXOSOMAL MICRORNAs AS POTENTIAL DIAGNOSTIC BIOMARKERS FOR FRONTOTEMPORAL DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P398.	0.4	0
257	P4â€525: ASSOCIATION OF CSF TAU WITH HYPERPLASTICITY IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P1515.	0.4	0
258	ICâ€Paâ€148: THE CORTICAL MICROSTRUCTURAL SIGNATURE OF ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2019, 15, P119.	0.4	0
259	O2â€09â€01: THE NATURAL HISTORY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME. <i>Alzheimer's and Dementia</i> , 2019, 15, P558.	0.4	0
260	AmyQ: An index to accurately measure cerebral amyloid load. <i>Alzheimer's and Dementia</i> , 2020, 16, e039735.	0.4	0
261	Oligodendroglial alterations in FTD caused by C9orf72 expansion. <i>Alzheimer's and Dementia</i> , 2020, 16, e040196.	0.4	0
262	Cerebrospinal fluid neuroinflammatory biomarkers along the Alzheimer disease continuum in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e041255.	0.4	0
263	Characteristics and prognosis of patients with mild cognitive impairment by cerebrospinal fluid biomarker profiles. <i>Alzheimer's and Dementia</i> , 2020, 16, e041500.	0.4	0
264	Quantifying the synaptic vesicle-associated protein, VAMP2, to verify changes in cerebrospinal fluid in preclinical stages of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042717.	0.4	0
265	Transcriptome characterization of the motor cortex suggests microglial-related key events due to TDPâ€43 aberrant inclusions. <i>Alzheimer's and Dementia</i> , 2020, 16, e042953.	0.4	0
266	1 Hâ€MRS signature in Alzheimer disease in Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, e043346.	0.4	0
267	Domiciliary Alzheimer visiting in Down syndrome pilot project: Preliminary results. <i>Alzheimer's and Dementia</i> , 2020, 16, e043491.	0.4	0
268	Longitudinal plasma levels of neurofilament light in Down syndrome: A multicenter study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044772.	0.4	0
269	Which pre-analytical confounder matters the most in the comparison of two cohorts? Tubes and storage fill volume put to the test. <i>Alzheimer's and Dementia</i> , 2020, 16, e045060.	0.4	0
270	VAMP2 is a cerebrospinal fluid marker of selective hippocampal synapse loss and episodic memory performance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045268.	0.4	0

#	ARTICLE	IF	CITATIONS
271	Blood-based detection of early-stage Alzheimer using multiomics and machine learning. Alzheimer's and Dementia, 2020, 16, e047334.	0.4	0
272	Late-onset epileptic seizures in adults with Down syndrome are linked to Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
273	Comparison of automated CLEIA and manual ELISA immunoassays for CSF AD biomarkers: The Fundaci3 ACE Biomarker Research Program (FACEBREP). Alzheimer's and Dementia, 2021, 17, .	0.4	0
274	A multimodal study on the effect of sex on Alzheimer's disease clinical and biomarker changes in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
275	Cortical microinfarcts along the Alzheimer's disease continuum in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
276	Neuropsychological correlates of plasma NfL in adults with Down syndrome. Alzheimer's and Dementia, 2021, 17, .	0.4	0
277	Alzheimer's disease clinical onset and age at death in people with Down syndrome: A systematic review and population-based study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
278	Plasma biomarkers for the AT(N) classification and for the detection of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
279	Transcriptome-wide characterization of the frontal cortex in FTLD.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e049569.	0.4	0